A 2025 clinical trial of ALZ-801 (valiltramiprosate) involving more than 300 adults age 50 or older who were genetically predisposed to Alzheimer's found that a subgroup of 125 participants with mild cognitive impairment at baseline showed a 52% slower rate of cognitive decline on one measured outcome compared with placebo.
October 29, 2025
high
statistical
Subgroup efficacy result from a 2025 randomized clinical trial of ALZ-801.
A 2025 clinical trial reported that participants treated with ALZ-801 experienced approximately 18% less hippocampal atrophy than placebo-treated participants.
October 29, 2025
high
statistical
Brain atrophy (hippocampal volume) comparison between ALZ-801 and placebo in a 2025 trial.
Individuals who carry two copies of the APOE4 allele (APOE4/4) have about ten times the typical risk of developing Alzheimer's disease; APOE4/4 carriers constitute about 2% of the general population but represent about 15% of people diagnosed with Alzheimer's disease.
October 29, 2025
high
epidemiological
APOE4/4 genotype-associated prevalence and relative risk for Alzheimer's disease.
ALZ-801 is an oral medication administered twice daily that is designed to inhibit aggregation of beta-amyloid proteins to prevent formation of amyloid plaques, whereas monoclonal-antibody Alzheimer's therapies are administered intravenously, act primarily by promoting breakdown of existing amyloid plaques, and are associated with risks of brain swelling or bleeding.
October 29, 2025
high
descriptive
Comparative mechanisms of an oral anti-aggregation agent versus intravenous monoclonal-antibody therapies in Alzheimer's treatment.
Acetylcholine levels generally begin a gradual decline around middle age and decline sharply in people with Alzheimer's disease.
October 22, 2025
high
temporal
Acetylcholine is a neurotransmitter closely associated with attention, memory, and other aspects of cognitive performance.